Advertisement

Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH09-06-0397
Issue:2010: 103/2 (Feb) pp. 251–479
Pages:338-343

Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics

S. Paneesha (1), A. McManus (2), R. Arya (3), N. Scriven (4), T. Farren (5), T. Nokes (6), S. Bacon (7), A. Nieland (8), D. Cooper (9), H. Smith (10), D. O'Shaughnessy (11), P. Rose (12); for the VERITY Investigators

(1) Consultant, Department of Haematology, Heart of England NHS Foundation Trust, Birmingham, UK; (2) Director, MMRx Consulting, Cheam, Surrey, UK; (3) Consultant, Departmentof Haematology, King's College Hospital, London, UK; (4) Consultant, Medical Assessment Unit, The Calderdale Royal Hospital, Halifax, UK; (5) Clinical Scientist, Departmentof Haematology, Barts and The London School of Medicine and Dentistry, London, UK; (6) Consultant, Department of Haematology, Derriford Hospital, Plymouth, UK; (7) Thrombosis Nurse Specialist, Scarborough Hospital, Scarborough, UK; (8) Thrombosis Nurse Specialist, Northampton General Hospital NHS Trust, Northampton, UK; (9) Statistical Consultant,London, UK; (10) Harry Smith, Medical Advisor, Sanofi Aventis UK*; (11) Special Advisor, Blood Policy Unit, Department of Health, London, UK; (12) Consultant, Departmentof Haematology, Warwick Hospital, Warwick, UK

Summary

Venous thromboembolism (VTE) is a clinically important complication for both hospitalised and ambulatory cancer patients. In the current study, the frequency, demographics and risk (according to tumour site) of VTE were examined among patients seen at outpatient DVT (deep-vein thrombosis) clinics. Of 10,015 VTE cases, 1,361 were diagnosed with cancer, for an overall rate of cancer-associated VTE of 13.6% in this outpatient population. Patients with cancer-associated VTE were significantly older than cancer-free VTE cases (66.4 ± 12.7 vs. 58.8 ± 18.5 years; p<0.0001). The frequency of cancer-associated VTE peaked earlier among females than males, occurring in the sixth (137/639, 21.4% vs. 98/851, 11.3%; p<0.001) and seventh decades (213/980, 21.7% vs. 197/1096, 18%; p=0.036). VTE was described most frequently in common cancers – breast, prostate, colorectal and lung (56.1% of cases). The risk of VTE varied widely across 17 cancer types. Calculating odds ratios (OR) to assess the effect size of cancer type on VTE risk, the highest odds were observed for patients with pancreatic cancer (OR 9.65, 95% confidence interval [CI] (5.51–16.91). Tumours of the head and neck had higher odds than previously reported (OR 8.24, 95% CI 5.06–13.42). Reduced risk estimates were observed for skin cancers (melanoma and non-melanoma: OR 0.89, 95% CI 0.42–1.87; OR 0.74, 95% CI, 0.32–1.69, respectively). We conclude that outpatients have a similar rate of cancer-associated VTE as VTE patient populations previously reported, that cancer-associated VTE occurs in an older age group and earlier in females and that outpatients exhibit distinct tumour site-specific risk from that described among hospitalised cancer patients.

Keywords

cancer, Venous thrombosis, clinical studies

DOI

http://dx.doi.org/10.1160/TH09-06-0397

You may also be interested in...

1.

Martin J. O’Donnell1, Simon McRae1, Susan R. Kahn2, Jim A. Julian1, Clive Kearon1, Betsy MacKinnon1, Debbie Magier3, Carla Strulovich2,Theresa Lyons1, Sandra Robinson3, Jack Hirsh1, Jeffrey S. Ginsberg1,2

Thrombosis and Haemostasis 2008 99 3: 623-629

http://dx.doi.org/10.1160/TH07-09-0546

2.

Nadine S. Gibson1, Maaike Sohne1, Marieke J. H. A. Kruip2, Lidwine W. Tick3, Victor E. Gerdes1, Patrick M. Bossuyt4, Philip S. Wells5, Harry R. Buller1 on behalf of the Christopher study investigators

Thrombosis and Haemostasis 2008 99 1: 229-234

http://dx.doi.org/10.1160/TH07-05-0321

3.

Ali Seddighzadeh, Ranjith Shetty, Samuel Z. Goldhaber

Thrombosis and Haemostasis 2007 98 3: 656-661

http://dx.doi.org/10.1160/TH07-04-0242



Articles

You've 210 Article(s) in your Basket.

TH107.2

With the expiry or pending expiry of originator low-molecular-weight heparin (LMWH) patents,...

TH 107.1

T&H has a new type of article! Read the first T&H Insights article by Lutgens et al. in the...

TH 106.6

Read the important position document from the European Heart Rhythm Association [EHRA] and the...